HIV infection and injecting drug users: The urgency of reinvigorating harm-reduction programmes
DOI:
https://doi.org/10.20882/adicciones.202Keywords:
injecting drug users, harm- and risk-reduction programmes, HIV prevention and management, injection-related HIV risk practices, sexrelated HIV risk practicesAbstract
The HIV epidemic among injecting drug users (IDUs) has led to greater support for the development of the harm-reduction perspective. This has proven to be a driving force for initially reluctant policy makers, managers and health care providers and has facilitated the implementation of harm-reduction programmes. This article presents recent data, both global and at the European and Spanish levels, about a) the epidemiological situation of HIV infection among IDUs, and b) the state of development of harm-reduction programmes. The incidence of HIV infection among IDUs not only continues to grow in different areas of, for example, Southeast Asia or Eastern Europe, but has even shown an upturn in cities or specific IDU groups in parts of Western Europe with apparently comprehensive harm-reduction strategies. On the other hand, of the 158 countries that acknowledge illegal drug use via injection in their territory, only 82 support harm reduction, explicitly in national policy documents and/or through the implementation or tolerance of interventions such as needle exchange programmes or opioid agonist programmes. These data, in conjunction with the high-quality and consistent evidence on the efficacy and effectiveness of harm- and risk-reduction programmes for HIV prevention and management among IDUs, should serve as a call to avoid complacency with regard to the diversification, accessibility and coverage of harm- and risk-reduction programmes for IDUs.References
Trujols J, Salazar JI, Salazar I. Los usuarios de drogas como ciudadanos: Los programas de reducción de daños. En: Becoña E, Salazar I, Rodríguez A, editores. Drogodependencias V. Avances. Santiago de Compostela: Universidade de Santiago de Compostela; 1999. p. 343-
Nadelmann E, McNeely J, Drucker E. International perspectives. En: Lowinson JH, Ruiz P, Millman RB, Langrod JG, editores. Substance abuse: A comprehensive textbook (3rd ed.). Baltimore, MD: Williams and Wilkins;
p. 22-39.
Mino A. Evolución de las políticas asistenciales en drogodependencias : En: Díaz M, Romaní O, coordinadores. Contextos, sujetos y drogas: Un manual sobre drogodependencias. Barcelona: Ajuntament de Barcelona y Fundación de Ayuda contra la Drogadicción; 2000. p. 333-68.
Aresi G, Fornari L, Repetto C, Scolari M. Evaluación de una intervención con conductores designados para prevenir los accidentes de tráfico provocados por el alcohol en las discotecas de Milán, Italia / Evaluation of a designated driver intervention to prevent alcohol-related road accidents in the clubs of Milan, Italy. Adicciones 2009; 21: 279-88.
Pereiro Gómez C, Bermejo Barrera A. Daños relacionados con el consumo de cocaína: la punta del iceberg es lo que vemos. Adicciones 2008; 20: 15-8.
Hagan H, Des Jarlais DC, Stern R, Lelutiu-Weinberger C, Scheinmann R, Strauss S, et al. HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection. Int J Drug Policy 2007; 18: 341-51.
Darke S, Degenhardt L, Mattick R. Mortality amongst illicit drug users. Cambridge: Cambridge University Press; 2007.
Ball AL. HIV, injecting drug use and harm reduction: A public health response. Addiction 2007; 102: 684-90.
Ezard N. Public health, human rights and the harm reduction paradigm: From risk reduction to vulnerability reduction. Int J Drug Policy 2001; 12: 207-19.
Rhodes T. The ‘risk environment’: A framework for understanding and reducing drug-related harm. Int J Drug Policy 2002; 13: 85-94.
Des Jarlais DC, Semaan S. HIV prevention for injecting drug users: the first 25 years and counting. Psychosom Med 2008; 70: 606-11.
Gowing L, Farrell M, Bornemann R, Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev 2008; (2): CD004145.
Wodak A, McLeod L. The role of harm reduction in controlling HIV among injecting drug users. AIDS 2008; 22 Supl 2: 81-92.
Spire B, Lucas GM, Carrieri MP. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Policy 2007; 18: 262-70.
Wood E, Kerr T, Tyndall MW, Montaner JSG. A review of barriers and facilitators of HIV treatment among injection drug users. AIDS 2008; 22: 1247-56.
Malta M, Magnanini MM, Strathdee SA, Bastos FI. Adherence to antiretroviral therapy among HIV-infected drug users: A meta-analysis [en prensa]. AIDS Behav.
Sharma M, Oppenheimer E, Saidel T, Loo V, Garg R. A situation update on HIV epidemics among people who inject drugs and national responses in South-East Asia Region. AIDS 2009; 23: 1405-13.
Wiessing L, van de Laar MJ, Donoghoe MC, Guarita B, Klempová D, Griffiths P. HIV among injecting drug users in Europe: increasing trends in the East. Euro Surveill 2008; 13(50). pii: 19067.
Judd A, Hickman M, Jones S, McDonald T, Parry JV, Stimson GV, et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: Prospective cohort study. Br Med J 2005; 330: 24-5.
Hope VD, Judd A, Hickman M, Sutton A, Stimson GV, Parry JV, et al. HIV prevalence among injecting drug users in England and Wales 1990-2003: Evidence for increased transmission in recent years. AIDS 2005; 19: 1207-14.
Vallejo F, Toro C, Brugal MT, de la Fuente L, Soriano V, Jiménez V, et al. Muy alta incidencia de VIH y VHC en jóvenes consumidores de heroína [resumen]. Gac Sanit 2006; 20 Espec Congr: 130.
Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008; 372: 1733-45.
Cook C, Kanaef N. The global state of harm reduction 2008. London: International Harm Reduction Association; 2008.
European Monitoring Centre for Drugs and Drug Addiction. Informe anual 2007: El problema de la drogodependencia en Europa. Luxemburgo: Oficina de Publicaciones Oficiales de las Comunidades Europeas;
European Monitoring Centre for Drugs and Drug Addiction. Informe anual 2008: El problema de la drogodependencia en Europa. Luxemburgo: Oficina de Publicaciones Oficiales de las Comunidades Europeas;
European Monitoring Centre for Drugs and Drug Addiction. Informe anual 2009: El problema de la drogodependencia en Europa. Luxemburgo: Oficina de Publicaciones Oficiales de las Comunidades Europeas;
Wiessing L, Olszewski D, Klempová D, Vicente J, Griffiths P. EMCDDA annual report 2009: cocaine and heroin maintain firm hold on Europe’s drug scene. Euro Surveill 2009; 14(46). pii: 19410.
Sutton AJ, Hope VD, Mathei C, Mravcik V, Sebakova H, Vallejo F, et al. A comparison between the force of infection estimates for blood-borne viruses in injecting drug user populations across the European Union: a
modelling study. J Viral Hepat 2008; 15: 809-16.
Barrio G, de la Fuente L, Toro C, Brugal MT, Soriano V, González F, et al. Prevalence of HIV infection among young adult injecting and non-injecting heroin users in Spain in the era of harm reduction programmes: gender differences and other related factors. Epidemiol Infect 2007; 135: 592-603.
Brugal MT, Toro C, Jiménez V, de la Fuente L, Ballesta R, Bravo MJ, et al. Prevalencia de inyección e infección por VIH y VHC entre jóvenes consumidores de cocaína que no consumen heroína [resumen]. Gac Sanit 2006; 20 Espec Congr: 130.
Centre d’Estudis Epidemiològics sobre l’HIV/SIDA de Catalunya. Sistema integrat de vigilància epidemiològica de l’HIV/SIDA a Catalunya: SIVES 2004. Barcelona: Departament de Salut de la Generalitat de Catalunya; 2005.
Centre d’Estudis Epidemiològics sobre l’HIV/SIDA de Catalunya. Sistema integrat de vigilància epidemiològica de l’HIV/SIDA a Catalunya: SIVES 2005. Barcelona: Departament de Salut de la Generalitat de Catalunya; 2006.
Folch C, Meroño M, Casabona J. Factores asociados a la práctica de compartir jeringuillas usadas entre usuarios de droga por vía parenteral reclutados en la calle. Med Clin (Barc) 2006; 127: 526-32.
Ministerio de Sanidad y Consumo. Plan multisectorial frente a la infección por VIH y el sida. España 2008-2012. Madrid: Ministerio de Sanidad y Consumo; 2008.
de la Fuente L, Bravo MJ, Toro C, Brugal MT, Barrio G, Soriano V, et al. Injecting and HIV prevalence among young heroin users in three Spanish cities and their association with the delayed implementation of harm reduction programmes. J Epidemiol Community Health 2006; 60: 537-42.
Bravo MJ, Royuela L, Barrio G, Brugal MT, Domingo A, de la Fuente L, et al. Acceso a jeringas estériles entre los jóvenes de Madrid y Barcelona que se inyectan drogas y su asociación con las prácticas de riesgo. Gac Sanit 2008; 22: 128-32.
de la Fuente L, Brugal MT, Domingo-Salvany A, Bravo MJ, Neira-León M, Barrio G. Más de treinta años de drogas ilegales en España: Una amarga historia con algunos consejos para el futuro. Rev Esp Salud Publica 2006; 80:505-20.
Bravo MJ, Royuela L, Barrio G, de la Fuente L, Suárez M, Brugal MT. More free syringes, fewer drug injectors in the case of Spain. Soc Sci Med 2007; 65: 1773-8.
de la Fuente L, Bravo MJ, Barrio G, Parras F, Suárez M, Rodés A, et al. Lessons from the history of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic among Spanish drug injectors. Clin
Infect Dis 2003; 37 Supl 5: 410-5.
Des Jarlais DC, Braine N, Yi H, Turner C. Residual injection risk behavior, HIV infection, and the evaluation of syringe exchange programs. AIDS Educ Prev 2007; 19: 111-23.
